secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2026-05-12T20:05:17+00:00
Accession:  0001193125-26-219367
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome Q1 2026 net loss $53.8M; NDA filed for varegacestat; cash $582.7M
--------------------------------------------------------------------------

- Net loss of $53.8M; R&D expenses $46.4M (incl. $3.7M stock comp); G&A $13.0M (incl. $4.2M stock comp).
- Cash and equivalents $582.7M at March 31, 2026; expected to fund operations into 2028.
- NDA submitted to FDA in April 2026 for varegacestat for desmoid tumors; Phase 3 RINGSIDE data selected for oral presentation at ASCO 2026.
- Phase 1 trial of IM-1021 ongoing with objective responses in B-cell lymphoma; initial lymphoma data expected in 2026.
- IND clearance for IM-1617 (first-in-class ADC) in April 2026; INDs for IM-1340 and IM-1335 planned mid/late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/0001193125-26-219367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/imnm-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer